Wanglong Gou^{1,4#}, Yuanqing Fu^{1,4#}, Liang Yue^{3,4#}, Geng-dong Chen^{2#}, Xue Cai^{3,4#}, Menglei Shuai^{1,4#}, Fengzhe Xu^{1,4#}, Xiao Yi^{3,4}, Hao Chen^{3,4}, Yi Zhu^{3,4}, Mian-li Xiao², Zengliang Jiang¹, Zelei Miao¹, Congmei Xiao¹, Bo Shen⁵, Xiaomai Wu⁵, Haihong Zhao⁵, Wenhua Ling², Jun Wang⁶, Yu-ming Chen^{2*}, Tiannan Guo^{3,4*}, Ju-Sheng Zheng^{1,4,7*}

¹Key Laboratory of Growth Regulation and Translation Research of Zhejiang Province, School of Life Sciences, Westlake University, Hangzhou 310024, China; ²Guangdong Provincial Key Laboratory of Food, Nutrition and Health; Department of Epidemiology, School of Public Health, Sun Yat-sen University, Guangzhou 510080, China;

³Key Laboratory of Structural Biology of Zhejiang Province, School of Life Sciences, Westlake University, Hangzhou 310024, China;

⁴Institute of Basic Medical Sciences, Westlake Institute for Advanced Study, Hangzhou 310024, China;

⁵Taizhou Hospital, Wenzhou Medical University, 150 Ximen Street, Linhai 317000, Zhejiang Province, China;

⁶ CAS Key Laboratory for Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, 100101, China.

⁷Lead Contact

#These authors contributed equally

*Correspondence: chenyum@mail.sysu.edu.cn (Y.M.C.); guotiannan@westlake.edu.cn (T.G.); zhengjusheng@westlake.edu.cn (J.S.Z.)

SUMMARY

1

2 The COVID-19 pandemic is spreading globally with high disparity in the susceptibility of the disease severity. Identification of the key underlying factors for 3 this disparity is highly warranted. Here we describe constructing a proteomic risk 4 score based on 20 blood proteomic biomarkers which predict the progression to 5 severe COVID-19. We demonstrate that in our own cohort of 990 individuals without 6 infection, this proteomic risk score is positively associated with proinflammatory 7 8 cytokines mainly among older, but not younger, individuals. We further discovered that a core set of gut microbiota could accurately predict the above proteomic 9 biomarkers among 301 individuals using a machine learning model, and that these gut 10 microbiota features are highly correlated with proinflammatory cytokines in another 11 12 set of 366 individuals. Fecal metabolomic analysis suggested potential amino acid-related pathways linking gut microbiota to inflammation. This study suggests 13 that gut microbiota may underlie the predisposition of normal individuals to severe 14 COVID-19. 15 16

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

3

healthy (non-infected) individuals to help explain the disease susceptibility. It is also

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

Poisson regression analysis indicated that per 10% increment in the PRS there was

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

5

microbiota and the above COVID-19-related PRS in a sub-cohort of 301 participants

with measurement of both gut microbiota (16s rRNA) and blood proteomics data

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

replicated in the independent prospective subset of 169 individuals, which showed a

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

inflammation.

in mediating the effect of the core gut microbiota on host metabolism and

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

Based on these key metabolites, we performed metabolic pathway analysis to elucidate possible biological mechanisms. The results showed that these 45 fecal metabolites were mainly enriched in three pathways, namely aminoacyl-tRNA biosynthesis pathway, arginine biosynthesis pathway, and valine, leucine and isoleucine biosynthesis pathway (Figure 4B). There were 15 fecal metabolites involved in the aminoacyl-tRNA biosynthesis pathway, which is responsible for adding amino acid to nascent peptide chains and is a target for inhibiting cytokine stimulated inflammation (Figure 4C). Additionally, 4 metabolites were associated with arginine biosynthesis pathway and 3 metabolites were enriched in valine, leucine and isoleucine (known as branch-chain amino acids, BCAAs) biosynthesis pathway (Figure 4C). Host and environmental factors modulate the PRS-related core microbial OTUs As demographic, socioeconomic, dietary and lifestyle factors may all be closely related to the gut microbiota, we explored the variance contribution of these host and environmental factors for the identified core OTU composition. A total of 40 items belonging to two categories (i.e., demographic/clinical factors and dietary/nutritional factors) were tested (Figure 5), which together explained 3.6% of the variation in interindividual distance of the core OTU composition (Bray-Curtis distance). In the demographic/clinical factors which explained 2.4% of the variation, we observed associations of 9 items (i.e., sex, education, physical activity, diastolic blood pressure, blood glucose, blood lipids and medicine use for type 2 diabetes) with inter-individual distances in the core OTU composition (PERMANOVA, p<0.05; Figure 5). While in the dietary/nutritional category (1.1% variance was explained), only dairy consumption significantly contributed to the variance of the core OTU composition. **Discussion** Our findings suggest that, among healthy non-infected individuals, gut microbial features are highly predictive of the blood proteomic biomarkers of severe COVID-19

disease. The disruption of the corresponding gut microbiome features may potentially

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

predispose healthy individuals to abnormal inflammatory status, which may further account for the COVID-19 susceptibility and severity. The fecal metabolomics analysis reveals that amino acid-related pathway may provide the key link between the identified core gut microbiota, inflammation and COVID-19 susceptibility. Furthermore, modifications on host and environmental factors are likely to influence the above core gut microbiota compositions. Accumulating evidence suggests that "cytokine storm", an excessive production of inflammatory cytokines, may be an important mechanism leading to the severity and death of COVID-19 patients (Huang et al., 2020; Yang et al., 2020). Therefore, anticytokine therapy for the suppression of the hyperinflammatory status of the patients is a recommended strategy to treat severe COVID-19 patients (Mehta et al., 2020; Monteleone et al., 2020). Among the 20 proteomic predictors of severe COVID-19, several most upregulated proteins are activated acute phase proteins, including serum amyloid A-1 (SAA1), SAA2, SAA4, alpha-1-antichymotrypsin (SERPINA3), complement 6 (C6) and complement factor B (CFB) (Shen et al., 2020). These proteins may be activated together with proinflammatory cytokines such as IL-6 and TNF-α following the invasion of the SARS-CoV-2. Therefore, this set of proteomic biomarkers may serve as an important biomarker or therapeutic target for treating SARS-CoV-2 infection. Beyond the previous data from the COVID-19 patients, our current study based on data from healthy non-infected participants consistently supports that the proteomic biomarkers (integrated into a score) are positively associated with proinflammatory cytokines, especially among those with an older age. These results imply that the proteomic changes my precede the progression of COVID-19 to severe phase. Moreover, our finding of more significant associations between PRS and proinflammatory cytokines among older people agree with the observation during COVID-19 outbreak that older individuals are more susceptible to the virus, leading to severity of the disease, due to the induced hyperinflammation or "cytokine storm" (Chen et al., 2020; Zhou et al., 2020).

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

In the present study, the core gut microbial features (20 OTUs), with a satisfied performance, outperform demographic characteristics and laboratory tests in predicting the blood proteomic biomarkers, which highlights a potential role of gut microbiota in regulating the susceptibility of COVID-19 among normal individuals. In fact, maintaining gut homeostasis has been suggested as a treatment option in the "Diagnosis and Treatment Plan of Corona Virus Disease 2019 (Tentative Sixth Edition)" issued by National Health Commission of China, as to keep the equilibrium for intestinal microecology and prevent secondary bacterial infection (National Health Commission (NHC) of the PRC, 2020). Growing evidence has shown that microbiota plays a fundamental role on the induction, training and function of the host immune system, and the composition of the gut microbiota and its activity are involved in production of inflammatory cytokines (Belkaid and Hand, 2014; Cani and Jordan, 2018). Prior studies reported that *Lactobacillus* genus was positively associated with IL-6 and IFN-γ, while Blautia genus was positively associated with IL-10 (Jiang et al., 2012; Pohjavuori et al., 2004; Yoshida et al., 2001); these relationships were replicated in our study. Besides, we found the PRS-related OTUs belonging to Bacteroides genus and Streptococcus genus were negatively associated with most proinflammatory factors. These results further support the reliability of the selected core OTUs. Fecal metabolomics analyses for the identified core gut microbial OTUs suggest that these OTUs may be closely associated with amino acid metabolism, especially aminoacyl-tRNA biosynthesis pathway, arginine biosynthesis pathway, and valine, leucine and isoleucine biosynthesis pathway. As metabolic stress pathways and nutrient availability instruct immunity, amino acid levels in the tissue microenvironment are central to the maintenance of immune homeostasis (Murray, 2016). Amino acid insufficiency will cause depletion of available aminoacylated tRNA, which is essential for the host to sense amino acid limitation and immune response (Brown et al., 2016, 2010; Harding et al., 2003). A recent study on several mammalian cell models reported that when aminoacyl-tRNA synthetase was inhibited,

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

the cytokine stimulated proinflammatory response would be substantially suppressed, and a single amino acid depletion, such as arginine or histidine, could also suppress the cytokine induced immune response (Kim et al., 2020). Thus the identified pathways regulating in aminoacyl-tRNA biosynthesis and arginine biosynthesis may be both involved in the inflammatory response. Additionally, arginine and BCAAs (i.e., valine, leucine and isoleucine), were also reported regulating innate and adaptive immune responses and enhancing intestinal development (Zhang et al., 2017). Collectively, these key roles that amino acids play in the immunoregulation may help explain how the PRS-related core OTUs modulate host inflammation via amino acid metabolism. Furthermore, given the high expression of ACE2 in the ileum and colon, and the role of ACE2 as a key regulator of dietary amino acid homeostasis and innate immunity (Hashimoto et al., 2012; Zhang et al., 2020), ACE2 may be another key mediator between gut microbiota and host inflammation. However, whether and how ACE2 may mediate the association between gut microbiota and COVID-19 severity warrants further mechanistic study. We observed that several host demographic and clinical factors had a strong effect on the identified core OTU composition, among which drug use and metabolic phenotypes had been widely reported correlating with gut microbiome composition (Cabreiro et al., 2013; Gilbert et al., 2018; Vich Vila et al., 2020). Although these observations were quite crude, it gave us an overview of the potential influence of host and environmental factors on the PRS-related gut microbiota matrix. Those known factors contributed to the COVID-19 susceptibility also contributed to the variance of the gut microbiota, including age, sex, and indicators of clinical comorbidities (blood pressure, glucose triglycerides, high-density and low-density lipoprotein cholesterol, and diabetes medication). In summary, our study provides novel insight that gut microbiota may underlie the susceptibility of the healthy individuals to the COVID-19. In the global crisis of COVID-19, a wide disparity in the susceptibility of the disease or disease progression

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

has been observed. Our results provide important evidence and suggestions about the potential biological mechanism behind the diverse susceptibility among different groups of people. The discovered core gut microbial features and related metabolites may serve as a potential preventive/treatment target for intervention especially among those who are susceptible to the SARS-CoV-2 infection. They could also serve as potential therapeutic targets for drug development. Acknowledgements This study was funded by the National Natural Science Foundation of China (81903316, 81773416, 81972492, 21904107, 81672086), Zhejiang Ten-thousand Talents Program (101396522001), Zhejiang Provincial Natural Science Foundation for Distinguished Young Scholars (LR19C050001), the 5010 Program for Clinical Researches (2007032) of the Sun Yat-sen University, Hangzhou Agriculture and Society Advancement Program (20190101A04), and Tencent foundation (2020). The funder had no role in study design, data collection and analysis, decision to publish, or writing of the manuscript. We thank Dr. C.R. Palmer for his invaluable comments to this study; and Westlake University Supercomputer Center for assistance in data storage and computation; and all the patients who consented to donate their clinical information and samples for analysis; and all the medical staff members who are on the front line fighting against COVID-19. **Author Contributions** Conceptualization, J.S.Z.; Methodology, W.G. and Y.F.; Formal Analysis, W.G., Y.F., L.Y., G.D.C, X.C., M.S., and F.X.; Investigation, M.L.X., B.S, X.W., H.Z., and W.H.L.; Data curation, X.Y., H.C., Y.Z., Z.J., Z.M. and C.X.; Resources, Y.M.C., T.G., J.S.Z; Writing, Y.F. and J.S.Z.; Writing-Review & Editing, J.S.Z, T.G., J.W, Y.F. and W.L.G; Visualization, M.S. and F.X.; Supervision, J.S.Z., Y.M.C., and T.G.; Funding Acquisition, J.S.Z., Y.M.C. and T.G. **Declaration of Interests**

The authors declare no competing financial interests

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

Figure Legends Figure 1. Study design and analysis pipeline. Study overview. 1) constructing a novel COVID-19 blood proteomic risk score (PRS) among 31 COVID-19 patients (18 non-severe cases and 13 severe cases). 2) Applicating the PRS in healthy participants, and further linking it to host inflammatory status (n=990). 3) Investigating the potential role of gut microbiota in predicting the PRS of COVID-19 based on a machine-learning method (n=301). 4) Assessing the relationships between the PRS-related gut microbiota and inflammatory factors (n=336). 5) Fecal metabolomics analysis reveals function of gut microbiota on host metabolism (n=987). 6) Investigating the impact of host and environmental factors on PRS-related core microbial OTUs (n=1729). Figure 2. Predictive proteomic profile for severe COVID-19 is correlated with pro-inflammatory factors among healthy individuals. (A) The associations of COVID-19-related blood proteomic biomarkers and proteomic risk score (PRS) with host inflammatory markers, 990 participants were involved in this analysis. # protein down-regulated in severe patients, else, up-regulated. (B) The correlation of the above blood proteomic biomarkers and PRS with host inflammatory markers stratified by the median age of participants (<58 years or ≥58 years). The color of the heatmap indicates the Spearman correlation coefficients (blue-negative, red-positive). (C) The correlation of the PRS with individual host inflammatory markers stratified by the median age of participants (<58 years or ≥ 58 years). Figure 3. Core microbiota features predict COVID-19 proteomic risk score (PRS) and host inflammation. (A) Plots of out-of-sample predicted PRS versus actual PRS based on top 20 ranked OTUs or demographic/clinical factors (age, sex BMI, fasting glucose, HDL, LDL, TC, TG, DBP, and SBP) using LightGBM with 10-fold cross-validation. The plots in the first row indicate the model performance among cross-sectional subset of individuals (n=132); the plots in the second row indicate the

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370371

model performance among prospective subset of individuals (n=169). The mean R² across the 10 cross validations, Pearson r of predicted values versus actual values, and corresponding P-value are shown in the figures. (B) The correlation of the core microbial OTUs and host inflammatory cytokines (n=336). The color of the heatmap indicates the Spearman correlation coefficients (blue-negative, red-positive). Figure 4. Fecal metabolome may be the key to link the proteomic risk score-related core microbial features and host inflammation (A) Associations of the core microbial OTUs with fecal metabolites (n=987). The relationships between microbial OTUs and fecal metabolites was assessed by a linear regression model adjusting for age, sex, BMI. Multiple testing was adjusted using Benjamini and Hochberg method, with a false discovery rate (FDR) of <0.05 being considered statistically significant. We only presented metabolites showing significant associations with more than half of the core microbial OTUs (n=20) in the figure. Sizes of the nodes represent the number of OTUs related with fecal metabolites. Red edge, β -coefficient >0; blue edge, β -coefficient <0. (**B**) Pathway analysis for the core fecal metabolites (shown in part A) using MetaboAnalyst 4.0 (Chong et al., 2019). (C) Metabolites enriched in the significant pathways (shown in part B). Figure 5. Host and environmental factors modulate the blood proteomic risk score-related core microbial OTUs. Host and environmental factors including 18 demographic/clinical items and 22 dietary/nutritional items were used in this analysis (n=1729). The bar plot indicates the explained variation of the core OTUs composition (Bray-Curtis distance) by each item. The heatmap next to the bar plot shows the correlation coefficients of each item with the core OTUs.

STAR MEHTODS 372 RESOURCE AVAILABILITY 373 374 Lead Contact Further information and requests for resources and reagents should be directed to and 375 will be fulfilled by the Lead Contact, Ju-Sheng Zheng 376 377 (zhengjusheng@westlake.edu.cn). 378 Materials Availability 379 This study did not generate new unique reagents. 380 381 Data and Code Availability 382 The raw data of 16 S rRNA gene sequences are available at CNSA 383 (https://db.cngb.org/cnsa/) of CNGBdb at accession number CNP0000829. 384 385 **SUBJECT DETAILS** 386 387 COVID-19 proteomics data set Detailed information about the COVID-19 patients and proteomics data set is 388 described in our recent publication (Shen et al., 2020). Briefly, the proteome of sera 389 from 46 COVID-19 patients and 53 control samples from Taizhou Public Health 390 Medical Center were analyzed by TMTpro 16 plex-based quantitative proteomics 391 technology. All the patients were diagnosed between January 23 and February 4, 2020. 392 According to the Chinese Government Diagnosis and Treatment Guideline for 393 COVID-19, the COVID-19 patients were classified into four groups, (1) mild (mild 394 395 symptoms without pneumonia); (2) typical (fever or respiratory tract symptoms with pneumonia); (3) severe (fulfill any of the three criteria: respiratory distress, 396 respiratory rate ≥ 30 times/min; mean oxygen saturation $\leq 93\%$ in resting state; 397 arterial blood oxygen partial pressure/oxygen concentration ≤ 300mmHg); and (4) 398 critical (fulfill any of the three criteria: respiratory failure and require mechanical 399 ventilation; shock incidence; admission to ICU with other organ failure). We treated 400

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

mild and typical patients as a non-severe COVID-19 group, and the others a severe COVID-19 group. Healthy subjects, sample collection, and clinical metadata In the present study, the healthy (non-infected) subjects are from the community-based Guangzhou Nutrition and Health Study (GNHS), and the detailed study designs of GNHS have been reported previously (Zhang et al., 2014). Briefly, participants were enrolled between 2008 and 2013, and followed up to May 2018. Blood samples were collected at enrollment and follow-up visits, and stool samples were collected only during follow-up visits. All the blood samples were collected as venous whole blood in the early morning before diet using serum separation tubes. The blood samples were centrifuged at 3,500 rpm for 10 min for serum collection. The serum samples were frozen at -80°C. The stool samples were collected at a local study site within the School of Public Health at Sun Yat-sen University, and were transferred to a -80°C facility within 4 hours after collection. Demographic and lifestyle factors were all collected by questionnaire during on-site face-to-face interviews. Habitual dietary intakes over the past 12 months were assessed by a food frequency questionnaire, as previously described (Zhang CX, 2009). Physical activity was assessed as a total metabolic equivalent for task (MET) hours per day on the basis of a validated questionnaire for physical activity (Liu et al., 2001). Anthropometric factors were measured by trained nurses on site during the baseline interview. Fasting venous blood samples were taken at each recruitment or follow-up visit. Serum low-density lipoprotein cholesterol and glucose were measured by coloimetric methods using a Roche Cobas 8000 c702 automated analyzer (Roche Diagnostics GmbH, Shanghai, China). Intra-assay coefficients of variation (CV) was 2.5% for glucose. Insulin was measured by electrochemiluminescence immunoassay (ECLIA) methods using a Roche cobas 8000 e602 automated analyzer (Roche

432

433

434

435

436

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456

457

458

459

Diagnostics GmbH, Shanghai, China). High-performance liquid chromatography was used to measure glycated hemoglobin (HbA1c) using the Bole D-10 Hemoglobin A1c Program on a Bole D-10 Hemoglobin Testing System, and the intraassay CV was 0.75%. Ethics This study has been approved by the Ethical/Institutional Review Board of Taizhou Public Health Medical Center, the Ethics Committee of the School of Public Health at Sun Yat-sen University and Ethics Committee of Westlake University. **METHOD DETAILS** Proteomic analysis 1 μL of serum sample from each patient was analyzed using proteomics technology. The serum was firstly denatured with 20 µL of buffer containing 8 M urea (Sigma, #U1230) in 100 mM ammonium bicarbonate at 30°C for 30 min. The lysates were reduced with 10 mM tris (2-carboxyethyl) phosphine (TCEP, Sigma #T4708) at room temperature for 30 min, and were then alkylated with 40 mM iodoacetamide (IAA, Sigma, #SLCD4031) in darkness for 45 min. The solution was then diluted with 70 μL 100 mM ammonium bicarbonate to make sure urea concentration is less than 1.6M, and was subjected to two times of tryptic digestion (Hualishi Tech. Ltd, Beijing, China), each step with 2.5 μL trypsin (0.4 μg/μL), at 32°C for 4 hr and 12 hr, respectively. Thereafter, the solution was acidified with 1% trifluoroacetic (TFA) (Thermo Fisher Scientific, #T/3258/PB05) to pH 2–3 to stop the reaction. Peptides were cleaned using C18 (Thermo, #60209-001). Peptide samples were then injected for LC-MS/MS analysis using an Eksigent NanoLC 400 System (Eksigent, Dublin, CA, USA) coupled to a TripleTOF 5600 system (SCIEX, CA, USA). Briefly, peptides were loaded onto a trap column (5 μm, $120 \text{ Å}, 10 \times 0.3 \text{ mm}$), and were separated along a 20 min LC gradient (5–32%)

461

462

463

464

465

466

467

468

469

470

471

472

473

474

475

476

477

478

479

480

481

482

483

484

485

486

487

488

489

buffer B, 98% ACN, 0.1% formic acid in HPLC water; buffer A: 2% ACN, 0.1% formic acid in HPLC water) on an analytical column (3 µm, 120 Å, 150 × 0.3 mm) at a flow rate of 5 µL/min. The SWATH-MS method is composed of a 100 ms of full TOF MS scan with the acquisition range of 350-1250 m/z, followed by MS/MS scans performed on all precursors (from 100 to 1500 Da) in a cyclic manner (Gillet et al., 2012). A 55-variable-Q1 isolation window scheme was used in this study. The accumulation time was set at 30 ms per isolation window, resulting in a total cycle time of 1.9 s. After SWATH acquisition, the Wiff files were converted into mzXML format using msconvert (ProteoWizard 3.0) (Kessner et al., 2008) and analyzed using OpenSWATH (2.1) (Kessner et al., 2008) against a pan human spectral library (Kessner et al., 2008) that contains 43899 peptide precursors and 1667 unique Swiss-Prot proteins protein groups. The retention time extraction window was set at 120 seconds, and the m/zextraction was performed with 30 ppm tolerance. Retention time was then calibrated using Common internal Retention Time standards (CiRT) peptides (Kessner et al., 2008). Peptide precursors were identified by OpenSWATH (version 2.0) and pyprophet (version 0.24) with FDR<0.01 to quantify the proteins in each sample. Measurement of inflammatory biomarkers For samples collected at baseline, Human FlowCytomix (Simplex BMS8213FF and BMS8288FF, eBioscience, San Diego, CA, USA) and the Human Basic Kit FlowCytomix (BMS8420FF, eBioscience, San Diego, CA, USA) on a BD FACSCalibur instrument (BD Biosciences, Franklin Lakes, NJ, USA) were used for the measurements of serum tumor necrosis factor (TNF-α), Interleukin-6 (IL-6), and Interleukin-1β (IL-1β). High-sensitivity CRP was measured using a [Cardiac C-Reactive Protein (Latex) High Sensitive (CRPHS) kit], and detected on a Cobas c701 automatic analyzer. The between-plate CVs were 14.1% for MCP1, 6.6% for TNF- α , 2.5% for IL-6, and 10.2% for IL-1 β .

491

492

493

494

495

496

497

498

499

500

501

502

503

504

505

506

507

508

509

510

511

512

513

514

515

516

517

518

519

For samples collected during follow-up visits, serum cytokine levels were assessed by electrochemiluminescence based immunoassays using the MSD V-Plex Proinflammatory Panel 1 (human) kit. 50 µL of serum derived from whole blood by centrifugation (10 min, 3,500 rpm) was processed according to the manufacturer's instructions. Briefly, the serum was diluted at a minimum of 2-fold dilution at first, while the detection antibodies were combined and added to 2400 µL of diluent. Thereafter, wash buffer and read buffer T were prepared as instructed. After finishing washing and adding samples, washing and adding detection antibody solution and washing plates again, then the plate could be analyzed on an MSD instrument. Accuracy and precision are evaluated by measuring calibrators across multiple runs and multiple lots. Intra-run coefficient of variations (CVs) are typically below 7% and inter-ran CVs are typically below 15%. In the present study, the inters-run CVs of calibrators were 2.2% for IL-1β, 2.5% for IL-2, 1.6% for IL-4, 1.7 for IL-6, 3.6 for IL-8, 2.5 for 1.3% for IL-10, 1.1% for IL-12p70, 0.87% for IL-13, TNF- α , 2.0% for IFN-γ. Microbiome analysis ---- DNA extraction Total bacterial DNA was extracted using the QIAamp® DNA Stool Mini Kit (Qiagen, Hilden, Germany) following the manufacturer's instructions. DNA concentrations were measured using the Qubit quantification system (Thermo Scientific, Wilmington, DE, US). The extracted DNA was then stored at -20 °C. Microbiome analysis ---- 16S rRNA gene amplicon sequencing The 16S rRNA gene amplification procedure was divided into two PCR steps, in the first PCR reaction, the V3-V4 hypervariable region of the 16S rRNA gene was amplified from genomic DNA using primers 341F(CCTACGGGNGGCWGCAG) and 805R(GACTACHVGGGTATCTAATCC). Amplification was performed in 96-well microtiter plates with a reaction mixture consisting of 1X KAPA HiFi Hot start Ready Mix, 0.1µM primer 341 F, 0.1 µM primer 805 R, and 12.5 ng template DNA giving a total volume of 50 µL per sample. Reactions were run in a T100 PCR thermocycle

521

522

523

524

525

526

527

528

529

530

531

532

533

534

535

536

537

538

539

540

541

542

543

544

545

546

547

548

549

(BIO-RAD) according to the following cycling program: 3 min of denaturation at 94 °C, followed by 18 cycles of 30 s at 94 °C (denaturing), 30 s at 55 °C (annealing), and 30 s at 72 °C (elongation), with a final extension at 72 °C for 5 min. Subsequently, the amplified products were checked by 2% agarose gel electrophoresis and ethidium bromide staining. Amplicons were quantified using the Qubit quantification system (Thermo Scientific, Wilmington, DE, US) following the manufacturers' instructions. Sequencing primers and adaptors were added to the amplicon products in the second PCR step as follows 2 µL of the diluted amplicons were mixed with a reaction solution consisting of 1×KAPA HiFi Hotstart ReadyMix, 0.5µM fusion forward and 0.5µM fusion reverse primer, 30 ng Meta-gDNA(total volume 50 µL). The PCR was run according to the cycling program above except with cycling number of 12. The amplification products were purified with Agencourt AMPure XP Beads (Beckman Coulter Genomics, MA, USA) according to the manufacturer's instructions and quantified as described above. Equimolar amounts of the amplification products were pooled together in a single tube. The concentration of the pooled libraries was determined by the Qubit quantification system. Amplicon sequencing was performed on the Illumina MiSeq System (Illumina Inc., CA, USA). The MiSeq Reagent Kits v2 (Illumina Inc.) was used. Automated cluster generation and 2 × 250 bp paired-end sequencing with dual-index reads were performed. Microbiome analysis ---- 16S rRNA gene sequence data processing Fastq-files were demultiplexed by the MiSeq Controller Software (Illumina Inc.). The sequence was trimmed for amplification primers, diversity spacers, and sequencing adapters, merge-paired and quality filtered by USEARCH. UPARSE was used for OTU clustering equaling or above 97%. Taxonomy of the OTUs was assigned and sequences were aligned with RDP classifier. The OTUs were analyzed by phylogenetic and operational taxonomic unit (OTU) methods in the Quantitative Insights into Microbial Ecology (QIIME) software version 1.9.0 (Caporaso et al., 2010).

551

552

553

554

555

556

557

558

559

560

561

562

563

564

565

566

567

568

569

570

571

572

573

574

575

576

577

578

579

Metabolomic analysis ---- sample preparation and instrumentation Targeted metabolomics approach was used to analyze fecal samples, with a total of 198 metabolites quantified. Feces samples were thawed on ice-bath to diminish degradation. About 10mg of each sample was weighed and transferred to a new 1.5mL tube. Then 25µL of water was added and the sample was homogenated with zirconium oxide beads for 3 minutes. 185µL of ACN/Methanol (8/2) was added to extract the metabolites. The sample was centrifuged at 18000g for 20 minutes. Then the supernatant was transferred to a 96-well plate. The following procedures were performed on a Biomek 4000 workstation (Biomek 4000, Beckman Coulter, Inc., Brea, California, USA). 20µL of freshly prepared derivative reagents was added to each well. The plate was sealed and the derivatization was carried out at 30°C for 60 min. After derivatization, 350µL of ice-cold 50% methanol solution was added to dilute the sample. Then the plate was stored at -20°C for 20 minutes and followed by 4000g centrifugation at 4 °C for 30 minutes. 135μL of supernatant was transferred to a new 96-well plate with 15µL internal standards in each well. Serial dilutions of derivatized stock standards were added to the left wells. Finally the plate was sealed for LC-MS analysis. An ultra-performance liquid chromatography coupled to tandem mass spectrometry (UPLC-MS/MS) system (ACQUITY UPLC-Xevo TQ-S, Waters Corp., Milford, MA, USA) was used to quantitate the microbial metabolite in the present study. The optimized instrument settings are briefly described below. ACQUITY UPLC BEH C18 1.7 µM VanGuard pre-column (2.1×5 mm) and ACQUITY UPLC BEH C18 1.7 μ M analytical column (2.1 × 100 mm) were used. The column temperature was 40°C and sample manager temperature was 10°C. Mobile phase A was water with 0.1% formic acid, and B was acetonitrile / IPA (90:10). The gradient conditions were as follows: 0-1 min (5% B), 1-12 min (5-80% B), 12-15 min (80-95% B), 15-16 min (95-100%B), 16-18 min (100%B), 18-18.1 min (100-5% B), 18.1-20 min (5% B), at a flow rate of 0.40 mL/min. The capillary of mass spectrometer were 1.5 (ESI+) and 2.0 (ESI-), while the source temperature and desolvation temperature was 150°C and

581

582

583

584

585

586

587

588

589

590

591

592

593

594

595

596

597

598

599

600

601

602

603

604

605

606

607

608

609

550°C, respectively. The desolvation gas flow was 1000 L/hour. *Metabolome analysis ---- Analytical quality control procedures* The rapid turnover of many intracellular metabolites makes immediate metabolism quenching necessary. The extraction solvents are stored in -20°C freezer overnight and added to the samples immediately after the samples were thawed. We use ice-salt bath to keep the samples at a low temperature and minimize sample degradation during sample preparation. All the prepared samples should be analyzed within 48 hours after sample extraction and derivatization. A comprehensive set of rigorous quality control/assurance procedures is employed to ensure a consistently high quality of analytical results, throughout controlling every single step from sample receipt at laboratory to final deliverables. The ultimate goal of QA/QC is to provide the reliable data for biomarker discovery study and/ or to aid molecular biology research. To achieve this, three types of quality control samples i.e., test mixtures, internal standards, and pooled biological samples are routinely used in the metabolomics platform. In addition to the quality controls, conditioning samples, and solvent blank samples are also required for obtaining optimal instrument performance. Test mixtures comprise a group of commercially available standards with a mass range across the system mass range used for the study samples. These samples were analyzed at the beginning and end of each batch run to ensure that the instruments were performing within laboratory specifications (retention time stability, chromatographic peak shape, and peak signal intensity). The retention time shift should be within 4 sec. and the difference of peak intensity should be within 15% for LC-MS. Internal standards were added to the test samples in order to monitor analytical variations during the entire sample preparation and analysis processes. The Pooled

611

612

613

614

615

616

617

618

619

620

621

622

623

624

625

626

627

628

629

630

631

632

633

634

635

636

637

638

OC samples were prepared by mixing aliquots of the study samples such that the pooled samples broadly represent the biological average of the whole sample set. The QC samples for this project were prepared with the test samples and injected at regular intervals (after every 14 test samples for LC-MS) throughout the analytical run. Reagent blank samples are a mixture of solvents used for sample preparation and are commonly processed using the same procedures as the samples to be analyzed. The reagent blanks serve as a useful alert to systematic contamination. As the reagent blanks consist of high purity solvents and are analyzed using the same methods as the study samples, they are also used to wash the column and remove cumulative matrix effects throughout the study. The calibrators consist of a blank sample (matrix sample processed without internal standard), a zero sample (matrix sample processed with internal standard), and a series of seven concentrations covering the expected range for the metabolites present in the specific biological samples. LLOQ and ULOQ are the lowest and highest concentration of the standard curve that can be measured with acceptable accuracy and precision. To diminish analytical bias within the entire analytical process, the samples were analyzed in group pairs but the groups were analyzed randomly. The QC samples, calibrators, and blank samples were analyzed across the entire sample set. Metabolome analysis ----Software and quantitation The raw data files generated by UPLC-MS/MS were processed using the QuanMET software (v2.0, Metabo-Profile, Shanghai, China) to perform peak integration, calibration, and quantification for each metabolite. The current QuanMET is hosted on Dell PowerEdge R730 Servers operated with Linux Ubuntu 16.10 OS.

640

641

642

643

644

645

646

647

648

649

650

651

652

653

654

655

656

657

658

659

660

661

662

663

664

665

666

667

668

The secured Java UI (User Interface) permits the user have access to use a great variety of statistical tools for viewing and exploring project data. Mass spectrometry-based quantitative metabolomics refers to the determination of the concentration of a substance in an unknown sample by comparing the unknown to a set of standard samples of known concentration (i.e., calibration curve). The calibration curve is a plot of how the analytical signal changes with the concentration of the analyte (the substance to be measured). For most analyses a plot of instrument response vs. concentration will show a linear relationship and the concentration of the measured samples were calculated. STATISTICAL ANALYSIS Dataset at each step of analyses among the healthy individuals from Guangzhou Nutrition and Health Study Dataset 1 (n=990): data from the baseline of GNHS. A total of 990 subjects with measurement of serum proteomics at baseline of the GNHS cohort were included in the initial discovery cohort. Among this initial discovery cohort, 455 subjects had data of serum IL-1β and IL-6, 456 subjects had data of serum TNF-α, and 953 subjects had serum hsCRP data. These data were used to investigate the relationship between the PRS and host inflammatory status. Dataset 2 (n=301): data from a follow-up visit of GNHS. A sub-cohort of 301 participants with measurement of both gut microbiota (16s rRNA) and blood proteomics data. Gut microbiota data were collected and measured during a follow-up visit of the cohort participants, with a cross-sectional subset of the individuals (n=132) having blood proteomic data at the same time point as the stool collection and another independent prospective subset of the individuals (n=169) having proteomic data at a next follow-up visit ~3 years later than the stool collection. Data from these subjects were used to explore the predictive capacity of the gut microbiota for PRS.

670

671

672

673

674

675

676

677

678

679

680

681

682

683

684

685

686

687

688

689

690

691

692

693

694

695

696

697

698

Dataset 3 (n=366): data from a follow-up visit of GNHS. Independent from the above 301 subjects in dataset 2, there were additionally 336 subjects with both fecal 16s rRNA sequencing and serum inflammatory cytokines data, at the same time point during follow-up. The data from these 336 subjects were used to examine the relationships between the core OTUs and 10 host inflammatory cytokines. Dataset 4 (n=987): data from a follow-up visit of GNHS. A total of 987 individuals had received fecal metabolomics and fecal microbiome examination at the same time point during the follow-up visit. These subjects were included in the analysis to assess the relationships between the core gut microbiota and fecal metabolomics. Dataset 5 (n=1729): data from a follow-up visit of GNHS. In total, 1729 participants finished food frequency questionnaire, demographic questionnaire and medical examination, and provided stool samples during follow-up. Thus, this subset of 1729 subjects were included to test how the dietary habits, lifestyle and health status influence the gut microbiota composition. In summary, a sum of 2413 healthy non-infected individuals are involved in the present study, which mainly consists of a subset of subjects with proteomic data at baseline (n=990) and a subset of subjects with gut microbiome and metabolome data at a follow-up visit (n=2172, within which 301 individuals also had proteomic data). Data imputation and presentation Missing values in proteomic features were imputed with 50% of the minimal value. Data are presented as mean \pm SD or percentage as indicated. Statistical tests used to compare conditions are indicated in figure legends. Unless otherwise stated, statistical analysis was performed using Python 3.7, R software (version 3.6.1, R foundation for Statistical Computing, Austria), and Stata 15 (StataCorp, College Station, TX, USA).

Construction of proteomic risk score (PRS)

We used 20 out of 22 previously identified proteomic biomarkers to construct a

proteomic risk score (PRS) for severe COVID-19 in COVID-19 patients and healthy

702 participants.

699

701

706

707

708

709

712

713

714

717

718

719

721

723

726

727

703
$$PRS_{i} = \sum_{j=1}^{20} \beta_{j} x_{ij}$$

Where, PRS_i is a proteomic risk score for individual i, 20 is the number of proteins

705 involved the score construction, x_{ij} is the Z score of abundance of the protein j for

individual i. β is 1 or -1 depending on the association between the protein j and risk of

progressing to clinically severe phase (1, up-regulated in severe patients, -1,

down-regulated in severe patients).

Association of PRS with the risk of progressing to clinically severe phase

Poisson regression model was used to examine the association of PRS with the risk of

progressing to clinically severe phase among 31 COVID-19 patients (18 non-severe

patients; 13 severe patients), adjusting for age, sex and BMI.

715 *Correlation between PRS and pro-inflammatory biomarkers*

Spearman correlation analysis was used to examine the correlation between PRS and

pro-inflammatory biomarkers (i.e., hsCRP, IL-1β, IL-6 and TNF-α). p<0.05 was

considered as statistically significant.

720 Machine learning algorithms for identifying microbial features to predict PRS

A 10-fold cross-validation (CV) implementation of gradient boosting framework

—LightGBM and SHAP (Shapley Additive exPlanations) was used to link input gut

microbial features with PRS (Ke et al., 2017; Lee, 2017). A 10-fold CV predict

724 implementation was used to generate a OTU-predicted PRS value for each participant.

In this approach, each LightGBM model is trained on 90% of the cohort with 10-fold

CV, and PRS is predicted for the 10% of the participants who were not used for model

optimization. This process is repeated ten-fold resulting in a test PRS set for each

729

730

731

732

733

734

735

736

737

738

739

740

741

742

743

744

745

746

747

748

749

750

751

752

753

754

755

756

participant and ten different average absolute SHAP value for each OTUs. The top 20 ranked OTUs based the sum of the average absolute SHAP value across ten-fold were included in further analysis. The R² score was computed by taking the mean of all the R² scores across the 10 out-of-sample predictions. Pearson r was calculated using actual PRS and predicted PRS for the entire cohort. We also compared the predictive performance for the top 20 ranked OTUs, demographic characteristics and laboratory tests (age, BMI, sex, blood pressure and blood lipids). Our predictor is based on code adapted from the sklearn 0.15.2 lightgbm regression (Pedregosa et al., 2011). The relationship between the identified core OTUs and host inflammatory cytokines Spearman correlation analysis was used to examine the correlation between PRS and cytokines (i.e., IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70, IL-13, TNF-α and IFN-γ). p<0.05 was considered as statistically significant. Relationship between OTUs and fecal metabolites Prior to the analysis, we excluded the participants with T2D medication use, and all fecal metabolites were natural logarithmic transformed to reduce skewness of traits distributions. Similarly, to reduce skewness of the distribution of microbial taxa counts, we first added 1 to all OTUs and then performed natural log transformation. The relationship between fecal metabolites and microbial OTUs was assessed by linear regression analysis while adjusting for age, sex, BMI. Multiple testing was adjusted using Benjamini and Hochberg method, with a false discovery rate (FDR) of < 0.05 being considered statistically significant. Metabolites showed significant associations with more than half of the selected microbial OTUs, were used for subsequent pathway analysis using MetaboAnalyst 4.0 (Chong et al., 2019). Associations of host and environmental factors with gut microbial features We assessed how many variations in the identified core OTUs composition (Bray-Curtis distance) can be explained by host and environmental factors (40 factors)

using the function *adonis* from the R package vegan. The p value was determined by 1000x permutations. The total variation explained was also calculated per category (demographic/clinical category and dietary/nutritional factors) and for all factors together. Spearman correlation analysis was used to assess the potential effect of each factor on each of the core OTU. Multiple testing was adjusted using Benjamini and Hochberg method, with a false discovery rate (FDR) of <0.05 being considered statistically significant.

766

767

768

769

770

771

772

773

774

775

776

777

778

779

780

781

782

783

784

785

786

787

788

789

790

791

792793

794

795 796 29

Supplementary Figure Legends Figure S1. Timeline of the participants enrollment, follow-up visit and sample collection in the Guangzhou Health and Nutrition Study. (A) At baseline, 4048 subjects provided completed metadata (required for analysis in the present study), and 1114 subjects provided blood samples (1114 for proteomic analysis and 990 for measurement of inflammatory factors). At follow-up visit, 2172 subjects provided stool samples (n=1729 for 16s rRNA sequencing; n=987 for metabolomic analysis), among which 667 subjects provided blood samples (n=301 for proteomic analysis; n=366 for measurement of inflammatory factors). (B) Detail information about the number of participants in the dataset1-dataset4 used in the present study. (C) Detail information about the number of participants in the dataset5 used in the present study. Figure S2. The correlation of the blood proteomic biomarkers and PRS with host inflammatory markers stratified by sex (n=990). The color of the heatmap indicates the Spearman correlation coefficients (blue-negative, red-positive). # protein down-regulated in severe patients, else, up-regulated. Figure S3. Co-variation of the core OTUs abundance and predictive proteomic biomarkers of COVID-19 (n=132). Co-inertia analysis of the relationship between 20 identified OTUs and 20 predictive proteomic biomarkers among a cross-sectional subset of 132 individuals. Each sample is represented with an arrow. The sample projection in the OTUs and the proteomic biomarkers space are represented by the starting point and the end of the arrow, respectively. Length of the arrow represents distance between the projections. (A, overall; B, age \geq 58; C, age \leq 58). **Supplementary Tables** Table S1. Characteristics of the data analysis sets Table S2. List of the 20 proteomic biomarkers integrated in the proteomic risk score Table S3. List and taxonomic classifications of the PRS-related core microbial **OTUs**

797 References


- 798 Belkaid, Y., and Hand, T.W. (2014). Role of the microbiota in immunity and
- 799 inflammation. Cell 157, 121–141.
- Brown, A., Fernández, I.S., Gordiyenko, Y., and Ramakrishnan, V. (2016).
- Ribosome-dependent activation of stringent control. Nature 534, 277–280.
- Brown, M. V, Reader, J.S., and Tzima, E. (2010). Mammalian aminoacyl-tRNA
- 803 synthetases: cell signaling functions of the protein translation machinery. Vascular
- 804 Pharmacology *52*, 21–26.
- 805 Cabreiro, F., Au, C., Leung, K.-Y., Vergara-Irigaray, N., Cochemé, H.M., Noori, T.,
- Weinkove, D., Schuster, E., Greene, N.D.E., and Gems, D. (2013). Metformin retards
- aging in C. elegans by altering microbial folate and methionine metabolism. Cell 153,
- 808 228–239.
- 809 Cani, P.D., and Jordan, B.F. (2018). Gut microbiota-mediated inflammation in obesity:
- a link with gastrointestinal cancer. Nature Reviews. Gastroenterology & Hepatology
- 811 15, 671–682.
- 812 Caporaso, J.G., Kuczynski, J., Stombaugh, J., Bittinger, K., Bushman, F.D., Costello,
- 813 E.K., Fierer, N., Peña, A.G., Goodrich, K., Gordon, J.I., et al. (2010). QIIME allows
- analysis of high-throughput community sequencing data. Nat Methods 7, 335–336.
- 815 Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., Qiu, Y., Wang, J., Liu, Y.,
- Wei, Y., et al. (2020). Epidemiological and clinical characteristics of 99 cases of 2019
- novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet (London,
- 818 England) 395, 507–513.
- 819 Chong, J., Wishart, D.S., and Xia, J. (2019). Using MetaboAnalyst 4.0 for
- 820 Comprehensive and Integrative Metabolomics Data Analysis. Current Protocols in
- Bioinformatics 68, e86.
- 822 Cole-Jeffrey, C.T., Liu, M., Katovich, M.J., Raizada, M.K., and Shenoy, V. (2015).
- 823 ACE2 and Microbiota: Emerging Targets for Cardiopulmonary Disease Therapy.
- Journal of Cardiovascular Pharmacology 66, 540–550.
- 625 Gilbert, J.A., Blaser, M.J., Caporaso, J.G., Jansson, J.K., Lynch, S. V, and Knight, R.
- 826 (2018). Current understanding of the human microbiome. Nature Medicine 24, 392–
- 827 400.
- 628 Gillet, L.C., Navarro, P., Tate, S., Röst, H., Selevsek, N., Reiter, L., Bonner, R., and
- Aebersold, R. (2012). Targeted data extraction of the MS/MS spectra generated by
- data-independent acquisition: a new concept for consistent and accurate proteome
- analysis. Mol. Cell. Proteomics. 11, O111.016717.
- Harding, H.P., Zhang, Y., Zeng, H., Novoa, I., Lu, P.D., Calfon, M., Sadri, N., Yun,
- 833 C., Popko, B., Paules, R., et al. (2003). An integrated stress response regulates amino
- acid metabolism and resistance to oxidative stress. Molecular Cell 11, 619–633.
- Hashimoto, T., Perlot, T., Rehman, A., Trichereau, J., Ishiguro, H., Paolino, M., Sigl,
- 836 V., Hanada, T., Hanada, R., Lipinski, S., et al. (2012). ACE2 links amino acid
- malnutrition to microbial ecology and intestinal inflammation. Nature 487, 477–481.
- 838 Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu,
- 839 X., et al. (2020). Clinical features of patients infected with 2019 novel coronavirus in
- Wuhan, China. Lancet (London, England) 395, 497–506.


- 841 Jiang, Y., Lü, X., Man, C., Han, L., Shan, Y., Qu, X., Liu, Y., Yang, S., Xue, Y., and
- Zhang, Y. (2012). Lactobacillus acidophilus induces cytokine and chemokine
- production via NF-κB and p38 mitogen-activated protein kinase signaling pathways in
- intestinal epithelial cells. Clinical and Vaccine Immunology: CVI 19, 603–608.
- 845 Jin, X., Lian, J.-S., Hu, J.-H., Gao, J., Zheng, L., Zhang, Y.-M., Hao, S.-R., Jia, H.-Y.,
- Cai, H., Zhang, X.-L., et al. (2020). Epidemiological, clinical and virological
- characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with
- gastrointestinal symptoms. Gut.
- 849 Ke, G., Meng, Q., Finley, T., Wang, T., Chen, W., Ma, W., Ye, Q., and Liu, T.-Y.
- 850 (2017). LightGBM: A Highly Efficient Gradient Boosting Decision Tree. Nips '17 9.
- Kessner, D., Chambers, M., Burke, R., Agus, D., and Mallick, P. (2008).
- ProteoWizard: open source software for rapid proteomics tools development.
- Bioinformatics (Oxford, England) 24, 2534–2536.
- Kim, Y., Sundrud, M.S., Zhou, C., Edenius, M., Zocco, D., Powers, K., Zhang, M.,
- Mazitschek, R., Rao, A., Yeo, C.-Y., et al. (2020). Aminoacyl-tRNA synthetase
- inhibition activates a pathway that branches from the canonical amino acid response
- in mammalian cells. Proceedings of the National Academy of Sciences of the United
- 858 States of America.
- Lee, S.M.L.S.-I. (2017). A Unified Apporach to Interpreting Model Predictions.
- 860 NIPS.
- 861 Lin, L., Jiang, X., Zhang, Z., Huang, S., Zhang, Z., Fang, Z., Gu, Z., Gao, L., Shi, H.,
- Mai, L., et al. (2020). Gastrointestinal symptoms of 95 cases with SARS-CoV-2
- 863 infection. Gut.
- 864 Liu, B., Woo, J., Tang, N., Ng, K., Ip, R., and Yu, A. (2001). Assessment of total
- energy expenditure in a Chinese population by a physical activity questionnaire:
- examination of validity. International Journal of Food Sciences and Nutrition 52,
- 867 269–282.
- Mehta, P., McAuley, D.F., Brown, M., Sanchez, E., Tattersall, R.S., and Manson, J.J.
- 869 (2020). COVID-19: consider cytokine storm syndromes and immunosuppression.
- 870 Lancet (London, England) 395, 1033–1034.
- Monteleone, G., Sarzi-puttini, P.C., and Ardizzone, S. (2020). Preventing
- 872 COVID-19-induced pneumonia with anticytokine therapy. The Lancet Rheumatology
- 873 *9913*, 30092–30098.
- Murray, P.J. (2016). Amino acid auxotrophy as a system of immunological control
- 875 nodes. Nature Immunology *17*, 132–139.
- National Health Commission (NHC) of the PRC, N.A. of T.C.M. of the P. (2020).
- 877 Diagnosis and Treatment Plan of Corona Virus Disease 2019 (Tentative Sixth
- 878 Edition). Guidance for Corona Virus Disease 2019: Prevention, Control and
- 879 Diagnosis and Management. Beijing, China: People's Medical Publishing House,.
- Ng, S.C., and Tilg, H. (2020). COVID-19 and the gastrointestinal tract: more than
- meets the eye. Gut.
- Pedregosa, F., Weiss, R., and Brucher, M. (2011). Scikit-learn: Machine Learning in
- 883 Python. 12, 2825–2830.
- Pohjavuori, E., Viljanen, M., Korpela, R., Kuitunen, M., Tiittanen, M., Vaarala, O.,

- and Savilahti, E. (2004). Lactobacillus GG effect in increasing IFN-gamma
- production in infants with cow's milk allergy. The Journal of Allergy and Clinical
- 887 Immunology 114, 131–136.
- 888 Shen, B., Yi, X., Sun, Y., Bi, X., Du, J., Zhang, C., Quan, S., Zhang, F., Sun, R., Qian,
- 889 L., et al. (2020). Proteomic and Metabolomic Characterization of COVID-19 Patient
- 890 Sera. MedRxiv, https://doi.org/10.1101/2020.04.07.20054585.
- Vich Vila, A., Collij, V., Sanna, S., Sinha, T., Imhann, F., Bourgonje, A.R., Mujagic,
- Z., Jonkers, D.M.A.E., Masclee, A.A.M., Fu, J., et al. (2020). Impact of commonly
- used drugs on the composition and metabolic function of the gut microbiota. Nature
- 894 Communications 11, 362.
- World Health Organization (2020). Coronavirus disease (COVID-19) Pandemic.
- 896 https://www.who.int/emergencies/diseases/novel-coronavirus-2019; Accessed Apr. 18,
- 897 2020
- 898 Yan, R., Zhang, Y., Li, Y., Xia, L., Guo, Y., and Zhou, Q. (2020). Structural basis for
- the recognition of SARS-CoV-2 by full-length human ACE2. Science (New York,
- 900 N.Y.) *367*, 1444–1448.
- 901 Yang, Y., Shen, C., Li, J., Yuan, J., Yang, M., Wang, F., Li, G., Li, Y., Xing, L., Peng,
- 902 L., et al. (2020). Exuberant elevation of IP-10, MCP-3 and IL-1ra during
- 903 SARS-CoV-2 infection is associated with disease severity and fatal outcome.
- 904 MedRxiv, https://doi.org/10.1101/2020.03.02.20029975.
- 905 Yoshida, K., Matsumoto, T., Tateda, K., Uchida, K., Tsujimoto, S., and Yamaguchi,
- 906 K. (2001). Induction of interleukin-10 and down-regulation of cytokine production by
- 907 Klebsiella pneumoniae capsule in mice with pulmonary infection. Journal of Medical
- 908 Microbiology 50, 456–461.
- 2009 Zhang, C.-X., and Ho, S.C. (2009). Validity and reproducibility of a food frequency
- 910 Questionnaire among Chinese women in Guangdong province. Asia Pacific Journal of
- 911 Clinical Nutrition 18, 240–250.
- 912 Zhang, H., Kang, Z., Gong, H., Xu, D., Wang, J., Li, Z., Li, Z., Cui, X., Xiao, J., Zhan,
- 913 J., et al. (2020). Digestive system is a potential route of COVID-19: an analysis of
- 914 single- cell coexpression pattern of key proteins in viral entry process. 1–9.
- 215 Zhang, S., Zeng, X., Ren, M., Mao, X., and Qiao, S. (2017). Novel metabolic and
- 916 physiological functions of branched chain amino acids: a review. Journal of Animal
- 917 Science and Biotechnology 8, 10.
- 918 Zhang, Z.-Q., He, L.-P., Liu, Y.-H., Liu, J., Su, Y.-X., and Chen, Y.-M. (2014).
- 919 Association between dietary intake of flavonoid and bone mineral density in middle
- aged and elderly Chinese women and men. Osteoporosis International: A Journal
- 921 Established as Result of Cooperation between the European Foundation for
- 922 Osteoporosis and the National Osteoporosis Foundation of the USA 25, 2417–2425.
- 923 Zhang CX, H.S. (2009). Validity and reproducibility of a food frequency
- 924 Questionnaire among Chinese women in Guangdong province. Asia Pac J Clin Nutr
- 925 18, 240–250.

- 926 Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B., Gu,
- 927 X., et al. (2020). Clinical course and risk factors for mortality of adult inpatients with
- 928 COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395, 1054–1062.

Figure 1





< 58 years</p>

≥ 58 years

* P < 0.05

** P < 0.01

*** P < 0.001


Correlation

-0.10.0 0.1 0.2

Figure 3

В










Figure 4





0.003

0.002

0.001

 \mathbb{R}^2

Figure 5

Demographic / clinical factors




Figure S1






Figure S2




Α

Overall



B ≥ 58 years



40

C < 58 years




Table S1. Characteristics of the data analysis set^a

Characteristics	dataset1	dataset2	dataset3	dataset4	dataset5
No. of participants	990	301	366	987	1729
Age (year)	58.79 (5.64)	66.21 (6.41)	66.09 (5.27)	64.71 (5.77)	58.54 (6.06)
Sex					
Women	668 (67.5%)	227 (75.4%)	241 (65.8%)	690 (69.9%)	1159 (67.0%)
Men	322 (32.5%)	74 (24.6%)	125 (34.2%)	297 (30.1%)	570 (33.0%)
BMI, kg/m ²	23.55 (3.23)	23.57 (3.04)	23.90 (3.65)	23.63 (3.26)	23.27 (3.08)
Marital status,%					
Married	911 (92.0%)	261 (87.0%)	342 (93.4%)	884 (89.6%)	1572 (90.9%)
Others	79 (8.0%)	39 (13.0%)	24 (6.6%)	103 (10.4%)	157 (9.1%)
Education,%					
Middle school or lower	294 (29.7%)	82 (27.3%)	88 (24.0%)	254 (25.7%)	469 (27.1%)
High school or professional	433 (43.7%)	116 (38.7%)	161 (44.0%)	434 (44.0%)	800 (46.3%)
college					
University	263 (26.6%)	102 (34.0%)	117 (32.0%)	299 (30.3%)	460 (26.6%)
Income (Yuan/month/person), %					
≤500	21 (2.1%)	3 (1.0%)	7 (1.9%)	11 (1.1%)	25 (1.4%)
501-1500	258 (26.1%)	70 (23.3%)	112 (30.6%)	235 (23.8%)	385 (22.3%)
1501-3000	565 (57.1%)	136 (45.2%)	177 (48.4%)	567 (57.4%)	1091 (63.1%)
>3000	146 (14.7%)	92 (30.6%)	70 (19.1%)	174 (17.6%)	228 (13.2%)
Current smoking status					
No	823 (83.1%)	268 (89.0%)	310 (84.7%)	858 (86.9%)	1458 (84.3%)
Yes	167 (16.9%)	33 (11.0%)	56 (15.3%)	129 (13.1%)	271 (15.7%)
Current alcohol drinking					
No	924 (93.3%)	289 (96.0%)	341 (93.2%)	914 (92.6%)	1604 (92.8%)
Yes	66 (6.7%)	12 (4.0%)	25 (6.8%)	73 (7.4%)	125 (7.2%)

^aValues are numbers (percentages) or mean (SD).

Table S2: List of the 20 proteomic biomarkers integrated in the proteomic risk score

Uniprot ID	Name	Annotation		
Q9UK55 SERPINA10		Protein Z-dependent protease inhibitor; Inhibits activity of the coagulation protease		
		factor Xa in the presence of PROZ, calcium and phospholipids. Also inhibits factor		
		XIa in the absence of cofactors; Belongs to the serpin family		
Q96PD5	PGLYRP2	N-acetylmuramoyl-L-alanine amidase; May play a scavenger role by digesting		
		biologically active peptidoglycan (PGN) into biologically inactive fragments. Has no		
		direct bacteriolytic activity; Belongs to the N-acetylmuramoyl-L-alanine amidase 2 family		
Q14520	HABP2	Hyaluronan-binding protein 2; Cleaves the alpha-chain at multiple sites and the beta-		
		chain between 'Lys-53' and 'Lys-54' but not the gamma-chain of fibrinogen and		
		therefore does not initiate the formation of the fibrin clot and does not cause the		
		fibrinolysis directly. It does not cleave (activate) prothrombin and plasminogen but		
		converts the inactive single chain urinary plasminogen activator (pro- urokinase) to		
		the active two chain form. Activates coagulation factor VII. May function as a tumor		
		suppressor negatively regulating cell proliferation and cell migration		
Q06033	ITIH3	Inter-alpha-trypsin inhibitor heavy chain H3; May act as a carrier of hyaluronan in		
		serum or as a binding protein between hyaluronan and other matrix protein, including		
		those on cell surfaces in tissues to regulate the localization, synthesis and degradation		
		of hyaluronan which are essential to cells undergoing biological processes		
P51884	LUM	Lumican; Small leucine rich repeat proteoglycans; Belongs to the small leucine-rich		
		proteoglycan (SLRP) family. SLRP class II subfamily		
P18428	LBP	Lipopolysaccharide-binding protein; Plays a role in the innate immune response.		
		Binds to the lipid A moiety of bacterial lipopolysaccharides (LPS), a glycolipid		
		present in the outer membrane of all Gram-negative bacteria. Acts as an affinity		
		enhancer for CD14, facilitating its association with LPS. Promotes the release of		
		cytokines in response to bacterial lipopolysaccharide; BPI fold containing		
P15169	CPN1	Carboxypeptidase N catalytic chain; Protects the body from potent vasoactive and		
		inflammatory peptides containing C-terminal Arg or Lys (such as kinins or		
		anaphylatoxins) which are released into the circulation; M14 carboxypeptidases		
P13796	LCP1	Plastin-2; Actin-binding protein. Plays a role in the activation of T-cells in response		
		to costimulation through TCR/CD3 and CD2 or CD28. Modulates the cell surface		
		expression of IL2RA/CD25 and CD69; EF-hand domain containing		
P13671	C6	Complement component C6; Constituent of the membrane attack complex (MAC)		
		that plays a key role in the innate and adaptive immune response by forming pores in		
		the plasma membrane of target cells; Complement system		
P12259	F5	Coagulation factor V; Central regulator of hemostasis. It serves as a critical cofactor		
		for the prothrombinase activity of factor Xa that results in the activation of		
		anothrombia to thrombia		
		prothrombin to thrombin		
P0DJI9	SAA2	Serum amyloid A-2 protein; Major acute phase reactant. Apolipoprotein of the HDL		
P0DJI9	SAA2			

endocytic lysosomal degradation.

Hemoglobin/haptoglobin complexes are rapidely cleared by the macrophage CD163 scavenger receptor expressed on the surface of liver Kupfer cells through an

Table S3: List and taxonomic classifications of the PRS-related core microbial OTUs

OTUs	Taxa annotation				
OTU30210_Clostridiales	k_Bacteria; p_Firmicutes; c_Clostridia; o_Clostridiales; f_; g_; s_				
spp					
OTU1090_Unassigned 2	Unassigned				
OTU174751_Clostridiu	k_Bacteria; p_Firmicutes; c_Clostridia; o_Clostridiales; f_Clostridiaceae; g_Clostridium; s_				
m spp					
OTU175355_Ruminococ	k_Bacteria; p_Firmicutes; c_Clostridia; o_Clostridiales; f_Lachnospiraceae;				
cus gnavus	g_[Ruminococcus]; s_gnavus				
OTU1954_Unassigned 1	Unassigned				
OTU198475_Ruminococ	$k_Bacteria; p_Firmicutes; c_Clostridia; o_Clostridiales; f_Ruminococcaceae; g_; s_$				
caceae spp 1					
OTU212681_Blautia spp	$k_Bacteria; p_Firmicutes; c_Clostridia; o_Clostridiales; f_Lachnospiraceae; g_Blautia; s_$				
OTU27582_Klebsiella	k_Bacteria; p_Proteobacteria; c_Gammaproteobacteria; o_Enterobacteriales;				
spp	f_Enterobacteriaceae; g_Klebsiella; s_				
OTU30109_Streptococcu	k_Bacteria; p_Firmicutes; c_Bacilli; o_Lactobacillales; f_Streptococcaceae;				
s spp 2	g_Streptococcus; s_				
OTU358_Bacteroides	k_Bacteria; p_Bacteroidetes; c_Bacteroidia; o_Bacteroidales; f_Bacteroidaceae;				
ovatus 2	g_Bacteroides; s_ovatus				
OTU3653_Bacteroides	k_Bacteria; p_Bacteroidetes; c_Bacteroidia; o_Bacteroidales; f_Bacteroidaceae;				
ovatus 1	g_Bacteroides; s_ovatus				
OTU437_Streptococcus	k_Bacteria; p_Firmicutes; c_Bacilli; o_Lactobacillales; f_Streptococcaceae;				
spp 1	gStreptococcus; s				
OTU662_Streptococcus	k_Bacteria; p_Firmicutes; c_Bacilli; o_Lactobacillales; f_Streptococcaceae;				
spp 3	gStreptococcus; s				
OTU743_Unassigned 3	Unassigned				
OTU808_Lactobacillus	$k_Bacteria; p_Firmicutes; c_Bacilli; o_Lactobacillales; f_Lactobacillaceae; g_Lactobacillus;$				
spp	s				
OTU87798_Bacteroides	k_Bacteria; p_Bacteroidetes; c_Bacteroidia; o_Bacteroidales; f_Bacteroidaceae;				
spp 2	g_Bacteroides; s_				
OTU87996_Bacteroides	k_Bacteria; p_Bacteroidetes; c_Bacteroidia; o_Bacteroidales; f_Bacteroidaceae;				
ovatus 3	g_Bacteroides; s_ovatus				
OTU88234_Bacteroides	k_Bacteria; p_Bacteroidetes; c_Bacteroidia; o_Bacteroidales; f_Bacteroidaceae;				
spp 3	g_Bacteroides; s_				
OTU91647_Ruminococc	k_Bacteria; p_Firmicutes; c_Clostridia; o_Clostridiales; f_Ruminococcaceae; g_; s_				
aceae spp 2					
OTU92227_Bacteroides	k_Bacteria; p_Bacteroidetes; c_Bacteroidia; o_Bacteroidales; f_Bacteroidaceae;				
spp 1	g_Bacteroides; s_				